Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Sanofi to Deliver Swine Flu Vaccine By Mid-October

By Drug Discovery Trends Editor | September 22, 2009

PARIS (AP) – Sanofi-Aventis SA will begin delivering the first doses of its new swine flu vaccine in the United States by mid-October, the head of France’s largest pharmaceutical company said Monday.

In an interview with French daily Le Figaro, Chris Viehbacher said Sanofi-Aventis will be able to produce at least 800 million doses of the vaccine per year.

Separately, the company’s vaccines division announced in a statement Tuesday that it had received a new order from the U.S. Department of Health and Human Services to produce the equivalent of 27.3 million doses, bringing the total U.S. order to 75.3 million doses.

As for deliveries in France, Viehbacher told Le Figaro that they could begin by late November, after approval by European drug regulators.

Last week the U.S. Food and Drug Administration approved the new swine flu vaccine, a long-anticipated step as the U.S. government works to start mass vaccinations next month.

The vaccine is being made by CSL Ltd. of Australia, Switzerland’s Novartis Vaccines, Maryland-based MedImmune LLC and Sanofi Pasteur of France – which produces flu shots at its Swiftwater, Pennsylvania, factory.

London-based GlaxoSmithKline also was expected to supply vaccine.

Typically fewer than 100 million Americans seek flu vaccine every year, and it’s unclear whether swine flu – what scientists prefer to call the 2009 H1N1 strain – will prompt much more demand.

Date: September 21, 2009
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50